Hyaluronan: Towards novel anti-cancer therapeutics

Pharmacological Reports

Volumn 65, Issue 5, 2013, Pages 1056-1074

  Karbownik, Michal S ^a   Nowak, Jerzy Z ^b,c  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c Medical Center MEDYCEUSZ   (Poland)

Author keywords

Anticancer drugs; Cancer; CD44; Drug delivery systems; Hyaluronan; Hyaluronan metabolism; Hyaluronan oligomers; RHAMM

Indexed keywords

HAS 2 PROTEIN; HAS 3 PROTEIN; HERMES ANTIGEN; HYALADHERIN; HYALURONAN MEDIATED MOTILITY PROTEIN; HYALURONIC ACID; IRINOTECAN; PACLITAXEL; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; BLADDER CANCER; BLADDER CARCINOMA; BURN; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRY EYE; EYE IRRITATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HAS 2 GENE; HAS 3 GENE; HEARING DISORDER; HISTORY OF MEDICINE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; ONCOGENE; OSTEOARTHRITIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKIN ULCER;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DESIGN; ENZYME INHIBITORS; EXTRACELLULAR MATRIX PROTEINS; GLUCURONOSYLTRANSFERASE; HUMANS; HYALURONIC ACID; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84894184903     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71465-8     Document Type: Article

References (146)

1. Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, Theocharis AD, Pavão MS et al.: Glycosaminoglycans: Key players in cancer cell biology and treatment. FEBS J, 2012, 279, 1177-1197.
2. Arai E, Nishida Y, Wasa J, Urakawa H, Zhuo L, Kimata K, Kozawa E et al.: Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo. Br J Cancer, 2011, 105, 1839-1849.
3. Auvinen P, Tammi R, Tammi M, Johansson R, Kosma VM: Expression of CD44s, CD44v3 and CD44v6 in benign and malignant breast lesions: Correlation and colocalization with hyaluronan. Histopathology, 2005, 47, 420-428. (Pubitemid 41428491)
4. Baumgartner G, Gomar-Hoss C, Sakr L, Ulsperger E, Wogritsch C: The impact of extracellular matrix on the chemoresistance of solid tumors-experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett, 1998, 131, 85-99. (Pubitemid 28467044)
5. Benitez A, Yates TJ, Lopez LE, Cerwinka WH, Bakkar A, Lokeshwar VB: Targeting hyaluronidase for cancer therapy: Antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res, 2011, 71, 4085-4095.
6. Bernert B, Porsch H, Heldin P: Hyaluronan synthase 2 (HAS2) promotes breast cancer cell invasion by suppression of tissue metalloproteinase inhibitor 1 (TIMP-1). J Biol Chem, 2011, 286, 42349-42359.
7. Bharadwaj AG, Kovar JL, Loughman E, Elowsky C, Oakley GG, Simpson MA: Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am J Pathol, 2009, 174, 1027-1036.
8. Bouga H, Tsouros I, Bounias D, Kyriakopoulou D, Stavropoulos MS, Papageorgakopoulou N, Theocharis DA, Vynios DH: Involvement of hyaluronidases in colorectal cancer. BMC Cancer, 2010, 10, 499.
9. Bourguignon LY, Gilad E, Peyrollier K, Brightman A, Swanson RA: Hyaluronan-CD44 interaction stimulates Rac1 signaling and PKNg kinase activation leading to cytoskeleton function and cell migration in astrocytes. J Neurochem, 2007, 101, 1002-1017. (Pubitemid 46683879)
10. Bourguignon LY, Singleton PA, Diedrich F, Stern R, Gilad E: CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 2004, 279, 26991-27007. (Pubitemid 38812535)
11. Bourguignon LY, Wong G, Earle C, Krueger K, Spevak CC: Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem, 2010, 285, 36721-36735.
12. Brinck J, Heldin P: Expression of recombinant hyaluronan synthase (HAS) isoforms in CHO cells reduces cell migration and cell surface CD44. Exp Cell Res, 1999, 252, 342-351. (Pubitemid 29530264)
13. Campo GM, Avenoso A, Campo S, D'Ascola A, Traina P, Calatroni A: Differential effect of molecular size HA in mouse chondrocytes stimulated with PMA. Biochim Biophys Acta, 2009, 1790, 1353-1367.
14. Chi A, Shirodkar SP, Escudero DO, Ekwenna OO, Yates TJ, Ayyathurai R, Garcia-Roig M et al.: Molecular characterization of kidney cancer: Association of hyaluronic acid family with histological subtypes and metastasis. Cancer, 2012, 118, 2394-2402.
15. Choi KY, Min KH, Yoon HY, Kim K, Park JH, Kwon IC, Choi K, Jeong SY: PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials, 2011, 32, 1880-1889.
16. Choi KY, Saravanakumar G, Park JH, Park K: Hyaluronic acid-based nanocarriers for intracellular targeting: Interfacial interactions with proteins in cancer. Colloids Surf B Biointerfaces, 2012, 99, 82-94.
17. Choi SH, Takahashi K, Eto H, Yoon SS, Tanabe KK: CD44s expression in human colon carcinomas influences growth of liver metastases. Int J Cancer, 2000, 85, 523-526. (Pubitemid 30075131)
18. Csoka AB, Frost GI, Stern R: The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol, 2001, 20, 499-508. (Pubitemid 33109098)
19. Cui X, Xu H, Zhou S, Zhao T, Liu A, Guo X, Tang W, Wang F: Evaluation of angiogenic activities of hyaluronan oligosaccharides of defined minimum size. Life Sci, 2009, 85, 573-577.
20. Cui X, Zhou S, Xu H, Zhao T, Liu A, Guo X, Wang F: Reversal effects of hyaluronan oligosaccharides on adriamycin resistance of K562/A02 cells. Anticancer Drugs, 2009, 20, 800-806.
21. Da Cunha CB, Oliveira C, Wen X, Gomes B, Sousa S, Suriano G, Grellier M et al.: De novo expression of CD44 variants in sporadic and hereditary gastric cancer. Lab Invest, 2010, 90, 1604-1614.
22. Darzynkiewicz Z, Balazs EA: Genome integrity, stem cells and hyaluronan. Aging (Albany NY), 2012, 4, 78-88.
23. De Sá VK, Olivieri E, Parra ER, Ab'Saber AM, Takagaki T, Soares FA, Carraro D et al.: Hyaluronidase splice variants are associated with histology and outcome in adenocarcinoma and squamous cell carcinoma of the lung. Hum Pathol, 2012, 43, 675-683.
24. Delpech B, Laquerriere A, Maingonnat C, Bertrand P, Freger P: Hyaluronidase is more elevated in human brain metastases than in primary brain tumours. Anticancer Res, 2002, 22, 2423-2427. (Pubitemid 34857077)
25. Desai B, Ma T, Zhu J, Chellaiah MA: Characterization of the expression of variant and standard CD44 in prostate cancer cells: Identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J Cell Biochem, 2009, 108, 272-284.
26. Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H et al.: CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res, 2008, 14, 6751-6760. [Erratum in: Clin Cancer Res, 2008, 14, 7964-7967.]
27. Duran-Reynals F: Exaltation de l'activité du virus vaccinal par les extraits de certains organs. CR Soc Biol, 1928, 99, 6-7.
28. Eissa S, Shehata H, Mansour A, Esmat M, El-Ahmady O: Detection of hyaluronidase RNA and activity in urine of schistosomal and non-schistosomal bladder cancer. Med Oncol, 2012, 29, 3345-3351.
29. Enegd B, King JA, Stylli S, Paradiso L, Kaye AH, Novak U: Overexpression of hyaluronan synthase-2 reduces the tumorigenic potential of glioma cells lacking hyaluronidase activity. Neurosurgery, 2002, 50, 1311-1318. (Pubitemid 36322773)
30. Evanko SP, Parks WT, Wight TN: Intracellular hyaluronan in arterial smooth muscle cells: Association with microtubules, RHAMM, and the mitotic spindle. J Histochem Cytochem, 2004, 52, 1525-1535. (Pubitemid 39603252)
31. Franzmann EJ, Schroeder GL, Goodwin WJ, Weed DT, Fisher P, Lokeshwar VB: Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer, 2003, 106, 438-445. (Pubitemid 36870409)
32. Frost GI, Mohapatra G, Wong TM, Csóka AB, Gray JW, Stern R: HYAL1LUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA. Oncogene, 2000, 19, 870-877. (Pubitemid 30153744)
33. Gaffney J, Matou-Nasri S, Grau-Olivares M, Slevin M: Therapeutic applications of hyaluronan. Mol Biosyst, 2010, 6, 437-443.
34. Gao AC, LouW, Dong JT, Isaacs JT: CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res, 1997, 57, 846-849. (Pubitemid 27098007)
35. Gao F, Cao M, Yang C, He Y, Liu Y: Preparation and characterization of hyaluronan oligosaccharides for angiogenesis study. J Biomed Mater Res B Appl Biomater, 2006, 78, 385-92. (Pubitemid 44167744)
36. Ghatak S, Misra S, Toole BP: Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem, 2005, 280, 8875-8883. (Pubitemid 40409577)
37. Ghatak S, Misra S, Toole BP: Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem, 2002, 277, 38013-38020. (Pubitemid 35154652)
38. Gibbs P, Clingan PR, Ganju V, Strickland AH, Wong SS, Tebbutt NC, Underhill CR et al.: Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: A randomized phase II trial. Cancer Chemother Pharmacol, 2011, 67, 153-163.
39. Girish KS, Kemparaju K, Nagaraju S, Vishwanath BS: Hyaluronidase inhibitors: A biological and therapeutic perspective. Curr Med Chem. 2009,16, 2261-2288.
40. Greiner J, Bullinger L, Guinn BA, Döhner H, Schmitt M: Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res, 2008, 14, 7161-7166.
41. Greiner J, Schmitt A, Giannopoulos K, Rojewski MT, Götz M, Funk I, Ringhoffer M et al.: High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica, 2010, 95, 1191-1197.
42. Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P et al.: RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia, 2009, 11, 956-963.
43. Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, McCarthy JB et al.: The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem, 2007, 282, 16667-16680. (Pubitemid 47100370)
44. Hamilton SR, Veiseh M, Tölg C, Tirona R, Richardson J, Brown R, Gonzalez M et al.: Pharmacokinetics and pharmacodynamics of hyaluronan infused into healthy human volunteers. Open Drug Metab J, 2009, 3, 43-55.
45. Hascall VC, Majors AK, De La Motte CA, Evanko SP, Wang A, Drazba JA, Strong SA, Wight TN: Intracellular hyaluronan: A new frontier for inflammation? Biochim Biophys Acta, 2004, 1673, 3-12. (Pubitemid 38844790)
46. Henle F: Vom Knorpelgewebe. Allgemeine Anatomielehre, von den Mischungs und Formbestandteilen des menschlichen Koerpers. Leopold Voss Verlag, Leipzig, 1841, 791-799.
47. Hong SC, Song JY, Lee JK, Lee NW, Kim SH, Yeom BW, Lee KW: Significance of CD44v6 expression in gynecologic malignancies. J Obstet Gynaecol Res, 2006, 32, 379-386.
48. Ibrahim S, Ramamurthi A: Hyaluronic acid cues for functional endothelialization of vascular constructs. J Tissue Eng Regen Med, 2008, 2, 22-32.
49. Itano N: Simple primary structure, complex turnover regulation and multiple roles of hyaluronan. J Biochem, 2008, 144, 131-137.
50. Itano N, Kimata K: Altered hyaluronan biosynthesis in cancer progression. Semin Cancer Biol, 2008, 18, 268-274.
51. Jacobson A, Rahmanian M, Rubin K, Heldin P: Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J Cancer, 2002, 102, 212-219. (Pubitemid 35222286)
52. Jiang D, Liang J, Noble PW: Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol, 2007, 23, 435-461.
53. Jiang P, Li X, Thompson CB, Huang Z, Araiza F, Osgood R, Wei G et al.: Effective targeting of the tumor microenvironment for cancer therapy. Anticancer Res, 2012, 32, 1203-1212.
54. Jówiak-Bêbenista M, Nowak JZ: Hyaluronan: Characteristics and practical applications in medicine (Polish). Farm Pol, 2010, 66, 882-893.
55. Karbownik MS, Nowak JZ: Hyaluronan in cancer-pathophysiology and pharmacotherapy perspectives (Polish). J Oncol, 2011, 61, 380-395.
56. Kauffman EC, Robinson VL, Stadler WM, Sokoloff MH, Rinker-Schaeffer CW: Metastasis suppression: The evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol, 2003, 169, 1122-1133. (Pubitemid 36188186)
57. Klocker J, Sabitzer H, Raunik W, Wieser S, Schumer J: Hyaluronidase as additive to induction chemotherapy in advanced squamous cell carcinoma of the head and neck. Cancer Lett, 1998, 131, 113-115. (Pubitemid 28467047)
58. Kogan G, Soltés L, Stern R, Gemeiner P: Hyaluronic acid: A natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol Lett, 2007, 29, 17-25. (Pubitemid 44950153)
59. Kopp R, Fichter M, Assert R, Pfeiffer AF, Classen S: Butyrate-induced alterations of phosphoinositide metabolism, protein kinase C activity and reduced CD44 variant expression in HT-29 colon cancer cells. Int J Mol Med, 2009, 23, 639-649.
60. Kouvidi K, Berdiaki A, Nikitovic D, Katonis P, Afratis N, Hascall VC, Karamanos NK, Tzanakakis GN: Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion. J Biol Chem, 2011, 286, 38509-38520.
61. Krasiñski R, Tchórzewski H: Hyaluronan-mediated regulation of inflammation (Polish). Postepy Hig Med Dosw, 2007, 61, 683-689.
62. Kung CI, Chen CY, Yang CC, Lin CY, Chen TH, Wang HS: Enhanced membrane-type 1 matrix metalloproteinase expression by hyaluronan oligosaccharides in breast cancer cells facilitates CD44 cleavage and tumor cell migration. Oncol Rep, 2012. 28, 1808-1814.
63. Kuo KT, Liang CW, Hsiao CH, Lin CH, Chen CA, Sheu BC, Lin MC: Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma. Mod Pathol, 2006, 19, 1570-1577.
64. Lai E, Singh R, Teng B, Zhao Y, Sharratt E, Howell G, Rajput A, Bullard Dunn K: Inhibition of hyaluronan synthase-3 decreases subcutaneous colon cancer growth in mice. Dis Colon Rectum, 2010, 53, 475-482.
65. Laznicek M, Laznickova A, Cozikova D, Velebny V: Preclinical pharmacokinetics of radiolabelled hyaluronan. Pharmacol Rep, 2012, 64, 428-437.
66. Lepperdinger G, Mullegger J, Kreil G: Hyal2-less active, but more versatile? Matrix Biol, 2001, 20, 509-514.
67. Lesley J, Hascall VC, Tammi M, Hyman R: Hyaluronan binding by cell surface CD44. J Biol Chem, 2000, 275, 26967-26975.
68. Liu L, Liu Y, Li J, Du G, Chen J: Microbial production of hyaluronic acid: Current state, challenges, and perspectives. Microb Cell Fact, 2011, 10, 99.
69. Lokeshwar VB, CerwinkaWH, Isoyama T, Lokeshwar BL: HYAL1 hyaluronidase in prostate cancer: A tumor promoter and suppressor. Cancer Res, 2005, 65, 7782-7789. (Pubitemid 41297253)
70. Lokeshwar VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, Escudero DO et al.: Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res, 2010, 70, 2613-2623.
71. Lokeshwar VB, Obek C, Soloway MS, Block NL: Tumor-associated hyaluronic acid: A new sensitive and specific urine marker for bladder cancer. Cancer Res, 1997, 57, 773-777. [Erratum in: Cancer Res 1998, 58, 3191.] (Pubitemid 27085665)
72. Lokeshwar VB, Rubinowicz D, Schroeder GL, Forgacs E, Minna JD, Block NL, Nadji M, Lokeshwar BL: Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem, 2001, 276, 11922-11932.
73. Lokeshwar VB, Selzer MG: Hyalurondiase: Both a tumor promoter and suppressor. Semin Cancer Biol, 2008, 18, 281-287.
74. Lopez JI, Camenisch TD, Stevens MV, Sands BJ, McDonald J, Schroeder JA: CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res, 2005, 65, 6755-6763. (Pubitemid 41060713)
75. Ma Q, Zhou Y, Ma B, Chen X, Wen Y, Liu Y, Fan Q, Qiu X: The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: A pilot study. Oncol Lett, 2012, 3, 797-801.
76. Martin-DeLeon PA: Epididymal SPAM1 and its impact on sperm function. Mol Cell Endocrinol, 2006, 250, 114-121.
77. Mateo M, Mollejo M, Villuendas R, Algara P, Sanchez-Beato M, Martínez P, Piris MA: 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol, 1999, 154, 1583-1589. (Pubitemid 29226452)
78. Matou-Nasri S, Gaffney J, Kumar S, Slevin M: Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and g-adducin. Int J Oncol, 2009, 35, 761-773.
79. Maxwell CA, Benítez J, Gómez-Baldó L, Osorio A, Bonifaci N, Fernández-Ramires R, Costes SV et al.: Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol, 2011, 9, e1001199.
80. Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Reiman T: Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Res, 2005, 65, 850-860. (Pubitemid 40216444)
81. Maxwell CA, McCarthy J, Turley E: Cell-surface and mitotic-spindle RHAMM: Moonlighting or dual oncogenic functions? J Cell Sci, 2008, 121, 925-932. (Pubitemid 351639411)
82. Maxwell CA, Rasmussen E, Zhan F, Keats JJ, Adamia S, Strachan E, Crainie M et al.: RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood, 2004, 104, 1151-1158. (Pubitemid 39038037)
83. Meyer K, Palmer JW: The polysaccharide of the vitreous humor. J Biol Chem, 1934, 107, 629-634.
84. Misra S, Ghatak S, Toole BP: Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem, 2005, 280, 20310-20315. (Pubitemid 40776728)
85. Misra S, Hascall VC, De Giovanni C, Markwald RR, Ghatak S: Delivery of CD44 shRNA/nanoparticles within cancer cells: Perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. J Biol Chem, 2009, 284, 12432-12446.
86. Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, Ghatak S: Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J, 2011, 278, 1429-1443.
87. Misra S, Obeid LM, Hannun YA, Minamisawa S, Berger FG, Markwald RR, Toole BP, Ghatak S: Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells. J Biol Chem, 2008, 283, 14335-14344.
88. Misra S, Toole BP, Ghatak S: Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem, 2006, 281, 34936-34941. (Pubitemid 46036532)
89. Mo W, Yang C, Liu Y, He Y, Wang Y, Gao F: The influence of hyaluronic acid on vascular endothelial cell proliferation and the relationship with ezrin/merlin expression. Acta Biochim Biophys Sin (Shanghai), 2011, 43, 930-939.
90. Monzon ME, Fregien N, Schmid N, Falcon NS, Campos M, Casalino-Matsuda SM, Forteza RM: Reactive oxygen species and hyaluronidase 2 regulate airway epithelial hyaluronan fragmentation. J Biol Chem, 2010, 285, 26126-26134.
91. Nagel S, Hirschmann P, Dirnhofer S, Günthert U, Tzankov A: Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. Exp Hematol, 2010, 38, 38-45.
92. Nakazawa H, Yoshihara S, Kudo D, Morohashi H, Kakizaki I, Kon A, Takagaki K, Sasaki M: 4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells. Cancer Chemother Pharmacol, 2006, 57, 165-170.
93. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV: Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol, 2008, 18, 260-267.
94. Nguyen VN, Mirejovský T, Melinová L, Mandys V: CD44 and its v6 spliced variant in lung carcinomas: Relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma, 2000, 47, 400-408.
95. Nowak JZ: Hyaluronan: Biochemical and functional aspects (Polish). Mag Lek Okul, 2010, 4, 37-49.
96. Nykopp TK, Rilla K, Tammi MI, Tammi RH, Sironen R, Hämälä inen K, Kosma VM et al.: Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma. BMC Cancer, 2010, 10, 512.
97. Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Holgado-Madruga M, Lanham IS et al.: Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol, 2002, 160, 441-447. (Pubitemid 34160321)
98. Okuda H, Kobayashi A, Xia B, Watabe M, Pai SK, Hirota S, Xing F et al.: Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res, 2012, 72, 537-547.
99. Orian-Rousseau V: CD44, a therapeutic target for metastasising tumours. Eur J Cancer, 2010, 46, 1271-1277.
100. Orian-Rousseau V, Ponta H: Adhesion proteins meet receptors: A common theme? Adv Cancer Res, 2008,101, 63-92.
101. Park D, Kim Y, Kim H, Kim K, Lee YS, Choe J, Hahn JH et al.: Hyaluronic acid promotes angiogenesis by inducing RHAMM-TGFb receptor interaction via CD44-PKCd. Mol Cells, 2012, 33, 563-574.
102. Park HY, Lee KJ, Lee SJ, Yoon MY: Screening of peptides bound to breast cancer stem cell specific surface marker CD44 by phage display. Mol Biotechnol, 2012, 51, 212-220.
103. Perng CK, Wang YJ, Tsi CH, Ma H: In vivo angiogenesis effect of porous collagen scaffold with hyaluronic acid oligosaccharides. J Surg Res, 2011, 168, 9-15.
104. Piccioni F, Malvicini M, Garcia MG, Rodriguez A, Atorrasagasti C, Kippes N, Piedra Buena IT et al.: Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. Glycobiology, 2012, 22, 400-410.
105. Pillwein K, Fuiko R, Slavc I, Czech T, Hawliczek G, Bernhardt G, Nirnberger G, Köller U: Hyaluronidase additional to standard chemotherapy improves outcome for children with malignant brain tumors. Cancer Lett, 1998, 131, 101-108. (Pubitemid 28467045)
106. Platt VM, Szoka FC Jr: Anticancer therapeutics: Targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm, 2008, 5, 474-486.
107. Prehm P; Hyaluronate is synthetized at plasma membranes. Biochem J, 1984, 220, 597-600.
108. Pujana MA, Han JD, Starita LM, Stevens KN, Tewari M, Ahn JS, Rennert G et al.: Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet, 2007, 39, 1338-1349. (Pubitemid 350035000)
109. Rajasagi M, Von Au A, Singh R, Hartmann N, Zöller M, Marhaba R: Anti-CD44 induces apoptosis in T lymphoma via mitochondrial depolarization. J Cell Mol Med, 2010, 14, 1453-1467.
110. Romero-Camarero I, Barajas-Diego M, Castellanos-Martín A, García-Martín Á, Varela G, Abad M, Ludeña MD et al.: New models towards assessing anti-cancer therapeutics. Histol Histopathol, 2012, 27, 157-170.
111. Rosato A, Banzato A, De Luca G, Renier D, Bettella F, Pagano C, Esposito G et al.: HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol Oncol, 2006, 24, 207-215.
112. Sharp JA, Plant JJ, Ohsumi TK, Borowsky M, Blower MD: Functional analysis of the microtubuleinteracting transcriptome. Mol Biol Cell, 2011, 22, 4312-4323.
113. Shigeishi H, Fujimoto S, Hiraoka M, Ono S, Taki M, Ohta K, Higashikawa K, Kamata N: Overexpression of the receptor for hyaluronan-mediated motility, correlates with expression of microtubule-associated protein in human oral squamous cell carcinomas. Int J Oncol, 2009, 34, 1565-1571.
114. Shuster S, Frost GI, Csoka AB, Formby B, Stern R: Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int J Cancer, 2002, 102, 192-197. (Pubitemid 35168035)
115. Simpson MA: Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice. Am J Pathol, 2006, 169, 247-257.
116. Simpson MA, Lokeshwar VB: Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci, 2008, 13, 5664-5680.
117. Sironen RK, Tammi M, Tammi R, Auvinen PK, Anttila M, Kosma VM: Hyaluronan in human malignancies. Exp Cell Res, 2011, 317, 383-391.
118. Slevin M, Krupinski J, Gaffney J, Matou S, West D, Delisser H, Savani RC, Kumar S: Hyaluronan-mediated angiogenesis in vascular disease: Uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol, 2007, 26, 58-68. (Pubitemid 46091650)
119. Stern R: Association between cancer and "acid mucopolysaccharides": An old concept comes of age, finally. Semin Cancer Biol, 2008, 18, 238-243.
120. Stern R: Hyaluronidases in cancer biology. Semin Cancer Biol, 2008, 18, 275-280.
121. Stern R, Asari AA, Sugahara KN: Hyaluronan fragments: An information-rich system. Eur J Cell Biol, 2006, 85, 699-715. (Pubitemid 44070579)
122. Stern R, Jedrzejas MJ: The hyaluronidases: Their genomics, structures, and mechanisms of action. Chem Rev, 2006, 106, 818-839.
123. Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M: Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J Biol Chem, 2005, 281, 5861-5868. (Pubitemid 43847686)
124. Takahashi Y, Li L, Kamiryo M, Asteriou T, Moustakas A, Yamashita H, Heldin P: Hyaluronan fragments induce endothelial cell differentiation in a CD44-and CXCL1/GRO1-dependent manner. J Biol Chem, 2005, 280, 24195-24204. (Pubitemid 40884909)
125. Tan JX, Wang XY, Su XL, Li HY, Shi Y, Wang L, Ren GS: Upregulation of HYAL1 expression in breast cancer promoted tumor cell proliferation, migration, invasion and angiogenesis. PLoS One, 2011, 6, e22836.
126. Telmer PG, Tolg C, McCarthy JB, Turley EA: How does a protein with dual mitotic spindle and extracellular matrix receptor functions affect tumor susceptibility and progression? Commun Integr Biol, 2011, 4, 182-185.
127. Teng BP, Heffler MD, Lai EC, Zhao YL, LeVea CM, Golubovskaya VM, Bullarddunn KM: Inhibition of hyaluronan synthase-3 decreases subcutaneous colon cancer growth by increasing apoptosis. Anticancer Agents Med Chem, 2011, 11, 620-628.
128. Tolg C, Hamilton SR, Morningstar L, Zhang J, Zhang S, Esguerra KV, Telmer PG et al.: RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity. J Biol Chem, 2010, 285, 26461-26474.
129. Tolg C, Hamilton SR, Nakrieko KA, Kooshesh F, Walton P, McCarthy JB, Bissell MJ, Turley EA: Rhamm-/-fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair. J Cell Biol, 2006, 175, 1017-1028. (Pubitemid 44969206)
130. Toole BP: Hyaluronan: From extracellular glue to pericellular cue. Nat Rev Cancer, 2004, 4, 528-539. (Pubitemid 38868622)
131. Toole BP: Hyaluronan-CD44 interactions in cancer: Paradoxes and possibilities. Clin Cancer Res, 2009, 15, 7462-7468.
132. Toole BP, Ghatak S, Misra S: Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr Pharm Biotechnol, 2008, 9, 249-252.
133. Underhill CB, Toole BP: Binding of hyaluronate to the surface of cultured cells. J Cell Biol, 1979, 82, 475-484. (Pubitemid 9241111)
134. Urakawa H, Nishida Y, Knudson W, Knudson CB, Arai E, Kozawa E, Futamura N et al.: Therapeutic potential of hyaluronan oligosaccharides for bone metastasis of breast cancer. J Orthop Res, 2012, 30, 662-672.
135. Urakawa H, Nishida Y, Wasa J, Arai E, Zhuo L, Kimata K, Kozawa E et al.: Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer, 2012, 130, 454-466.
136. Wallach-Dayan SB, Rubinstein AM, Hand C, Breuer R, Naor D: DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis. Mol Cancer Ther, 2008, 7, 1615-1623.
137. Wang SJ, Earle C, Wong G, Bourguignon LY: Role of hyaluronan synthase 2 to promote CD44-dependent oral cavity squamous cell carcinoma progression. Head Neck, 2012, doi: 10.1002/hed.22991.
138. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY: CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope, 2009, 119, 1518-1530.
139. Wang YZ, Cao ML, Liu YW, He YQ, Yang CX, Gao F: CD44 mediates oligosaccharides of hyaluronan-induced proliferation, tube formation and signal transduction in endothelial cells. Exp Biol Med (Maywood), 2011, 236, 84-90.
140. Ween MP, Hummitzsch K, Rodgers RJ, Oehler MK, Ricciardelli C: Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. Clin Exp Metastasis, 2011, 28, 113-125.
141. Whatcott CJ, Han H, Posner RG, Hostetter G, Von Hoff DD: Targeting the tumor microenvironment in cancer: Why hyaluronidase deserves a second look. Cancer Discov, 2011, 1, 291-296.
142. Yoffou PH, Edjekouane L, Meunier L, Tremblay A, Provencher DM, Mes-Masson AM, Carmona E: Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer. PLoS One, 2011, 6, e20705.
143. Yu Q, Stamenkovic I: Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev, 1999, 13, 35-48. (Pubitemid 29045114)
144. Zabarovsky ER, Lerman MI, Minna JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene, 2002, 21, 6915-6935. (Pubitemid 35221938)
145. Zeng C, Toole BP, Kinney SD, Kuo JW, Stamenkovic I: Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer, 1998, 77, 396-401. (Pubitemid 28299876)
146. Zhu D, Bourguignon LYW: Interaction between CD44 and the repeat domain of ankyrin promotes hyaluronic acid-mediated ovarian tumor cell migration. J Cell Physiol, 2000, 183, 182-195. (Pubitemid 30185937)